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Background: In patients with arterial hypertension, increased blood pressure (BP) vari-
ability contributes to end organ damage independently from mean levels of arterial BP.
Increased BP variability has been linked to alterations in autonomic function including sym-
pathetic overdrive. We hypothesized that catheter-based renal sympathetic denervation
(RDN) confers beneﬁcial effects on BP variability. Methods and Results: Eleven consecu-
tive patients with therapy-refractory arterial hypertension (age 68.9± 7.0 years; baseline
systolic BP 189± 23mmHg despite medication with 5.6± 2.1 antihypertensive drugs)
underwent bilateral RDN. Twenty-four hour ambulatory BP monitoring (ABPM) was per-
formed before RDN and 6months thereafter. BP variability was primarily assessed by
means of standard deviation of 24-h systolic arterial BP (SDsys). Secondary measures of
BP variability were maximum systolic BP (MAXsys) and maximum difference between two
consecutive readings of systolic BP (Δmaxsys) over 24 h. Six months after RDN, SDsys,
MAXsys, and Δmaxsys were signiﬁcantly reduced from 16.9± 4.6 to 13.5± 2.5mmHg
(p= 0.003), from190± 22 to 172± 20mmHg (p< 0.001), and from40± 15 to 28± 7mmHg
(p= 0.006), respectively, without changes in concomitant antihypertensive therapy. Reduc-
tions of SDsys, MAXsys, and Δmaxsys were observed in 10/11 (90.9%), 11/11 (100%), and
9/11 (81.8%) patients, respectively. Although we noted a signiﬁcant reduction of systolic
ofﬁce BP by 30.4± 27.7mmHg (p= 0.007), there was only a trend in reduction of average
systolic BP assessed from ABPM (149± 19 to 142± 18mmHg; p= 0.086). Conclusion: In
patients with therapy-refractory arterial hypertension, RDN leads to signiﬁcant reductions
of BP variability. Effects of RDN on BP variability over 24 h were more pronounced than on
average levels of BP.
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INTRODUCTION
Reductions of systolic and diastolic blood pressure (BP) are the
primary goal in treatment of arterial hypertension (Mancia et al.,
2007b). Several large-scale studies demonstrated a clear relation-
ship between level of BP and cardiovascular risk. However, even
under physiologic conditions BP is a highly variable parameter
inﬂuenced by a variety of intrinsic and extrinsic factors. There is
sound evidence that increased BP variability and instability con-
tribute to end organ damage, independently from absolute BP
levels (Parati et al., 1987; Frattola et al., 1993; Sander et al., 2000;
Mancia et al., 2001; Pringle et al., 2003; Hansen et al., 2010; Roth-
well et al., 2010b). Patients with treatment-resistant BP variability
are known to have a poor prognosis even if their mean BP is
under control (Rothwell, 2010; Rothwell et al., 2010b). Therefore,
knowledge about the effect of an antihypertensive therapy on BP
variability is of clinical importance.
Several factors have been associated with increased BP variabil-
ity including advanced age, diabetes mellitus, and female gender
(Mancia et al., 1983; Rothwell, 2010; Schillaci and Parati, 2010).
However, the exact pathophysiological mechanisms underlying
abnormal BP variability and instability are still debated. Auto-
nomic factors including sympathetic overactivity and blunted
arterial baroreﬂex function are most likely involved (Mancia et al.,
1983, 1997; Rothwell, 2010; Schillaci et al., 2011).
Catheter-based renal sympathetic denervation (RDN) is a novel
treatment option for patients with uncontrolled essential arterial
hypertension (Krum et al., 2009; Esler et al., 2010). Basic principle
of RDN is bilateral radiofrequency ablation of afferent and effer-
ent sympathetic nerves located in the adventitia of the renal artery.
RDN has been shown to effectively reduce systolic and diastolic BP
most probably due to a reduction in both renal and central sympa-
thetic activity (Krum et al., 2009; Esler et al., 2010). RDN reduces
whole body norepinephrine spillover by 42% and efferent muscle
sympathetic nerve activity by 66% (Schlaich et al., 2009). How-
ever, effects of RDN on BP variability and instability are entirely
unknown.
In the present study,we tested the hypothesis that RDN leads to
a signiﬁcant reduction of abnormal BP variability and instability
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in patients with therapy-refractory arterial hypertension in depen-
dently from a reduction in mean BP levels.
MATERIALS AND METHODS
PATIENTS
The present study included the ﬁrst 11 patients who underwent
RDN in our hospital. All patients suffered from therapy-refractory
arterial hypertension. Enrollment criteria were identical to those
used in previous studies (Krum et al., 2009; Esler et al., 2010).
Patients were above 18 years of age, had an ofﬁce systolic BP of
≥160 mmHg (≥150 mmHg for patients with type 2 diabetes mel-
litus) despite being treated with at least three antihypertensive
drugs (including one diuretic), with no changes in medication for
a minimum of 2 weeks before enrollment. Patients were included
if they were not pregnant and had an estimated glomerular ﬁl-
tration rate ≥45 mL min−1 1.73 m−2 (using the Modiﬁed Diet in
Renal Disease formula). All patients underwent a complete his-
tory and physical examination, assessment of vital signs, review of
medication, and blood chemistry at baseline and after 6 months.
Physicians were instructed not to change antihypertensive med-
ications except when medically required. Patients were instructed
to remain adherent to their prescribed drugs and deﬁned doses
during follow-up. The study was approved by the ethic committee
of the University of Tübingen. All patients gave written informed
consent.
RENAL DENERVATION PROCEDURE
Patients underwent RDN between October 2010 and March 2011.
Details of RDN have been described elsewhere (Krum et al., 2009;
Esler et al., 2010). Renal angiograms were performed via femoral
access to conﬁrmanatomic eligibility. The treatment catheter (Flex
by Ardian/Medtronic Inc., Mountain View, USA) was introduced
into each renal artery using a guiding catheter. Up to six ablations
at eight watts for 2 min each were performed in both renal arteries.
Treatments were delivered from the ﬁrst distal main renal artery
bifurcation to the ostium proximally and were spaced longitudi-
nally and rotationally under ﬂuoroscopic guidance. Catheter tip
impedance and temperaturewere constantlymonitored, and radio
frequency energy delivery was regulated according to a predeter-
mined algorithm. Visceral pain at the time of energy delivery was
managed with intravenous analgesics and sedatives. Heparin was
given to achieve an activated clotting time during the procedure
of more than 250 s.
ASSESSMENT OF BP, BP VARIABILITY, AND INSTABILITY
OfﬁceBP readingswere taken in a seatedposition after 5 minof rest
according to the standard JointNational CommitteeVII guidelines
before ablation and 6 months thereafter (Chobanian et al., 2003).
Averages of triplicate consecutive measures were used. Patients
with reductions of systolic ofﬁce BP of more than 10 mmHg were
regarded as responders (Mahfoud et al., 2011).
In all patients, 24-h ambulatory BP monitoring (ABPM;
oscillometric Spacelabs 90207-32 monitor, Spacelabs Healthcare,
Issaquah, WA, USA) was performed before RDN and 6 months
thereafter. Readings were taken every 20 min during daytime and
every 60 min at night-time. Only ambulatory BP assessments that
met European Society of Cardiology and European Society of
Hypertension guidelines (with more than 70% of daytime and
night-time readings) were regarded as technically sufﬁcient for
inclusion in the analysis (Mancia et al., 2007b). Mean systolic
and diastolic BP was calculated as overall 24-h averages for every
patient. BP variability was assessed by the standard deviation of
systolic and diastolic BP (SDsys and SDdia; Mancia et al., 2007b),
the maximum systolic and diastolic BP (MAXsys and MAXdia),
and the maximum difference of systolic and diastolic BP observed
between two consecutive readings (Δmaxsys and Δmaxdia). Mean
and standard deviations of systolic and diastolic BP were also cal-
culated for day (10 AM–8 PM) and night-time (12 AM–6 AM).
The coefﬁcient of variationof systolic anddiastolic BPwas assessed
by dividing SD by mean. We also assessed the morning surge, i.e.,
the maximum increase in systolic and diastolic BP between 4 AM
and 10 AM.
STATISTICAL ANALYSIS
Data are expressed as mean± standard deviation. Wilcoxon
signed-rank test for two related samples was used to compare
continuous variables assessed before and after RDN. All tests of
signiﬁcance were two-sided. Analyses of the effects of RDN on
SDsys were speciﬁed as primary analyses. Analyses of the effects
of RDN on other measures of BP were only exploratory. Pearson’s
correlation was used to test the correlation between continuous
variables. A two-tailed p-value <0.05 was considered statistically
signiﬁcant.
Taking into consideration the effects of calcium antagonists
on our primary variable (Frattola et al., 2000) we hypothesized a
minimum RDN-induced reduction of 30% in SDsys. To achieve
a power of 90% with a standard deviation of SDsys = 3.8 mmHg
(Mancia et al., 2001) we calculated the minimum required sample
size for a paired analysis to n = 8 (R CRAN 2.13.1, package sample
size).
SPSS software for Windows (version 13.0; SPSS, Chicago, IL,
USA) was used for all other statistical analyses.
RESULTS
Tables 1 and 2 show the demographic indicators and clinical
characteristics. Three patients were female. Mean age was 68.9
(7.0) years. On average, patients were taking 5.6 (2.1) antihy-
pertensive drugs. All patients received an angiotensin-converting
enzyme inhibitor, angiotensin II receptor blocker, or both; six
patients (54.5%) received a direct renin-inhibitor, eight patients
(72.7%) received β-blockers; nine (81.8%) were taking calcium
channel blockers; and eight (72.7%) received centrally acting sym-
patholytic agents. Two patients were on vasodilators (18.2%) and
four on α-blockers (36.4%). All patients received diuretics, with 2
(18.2%) taking aldosterone antagonists.
Renal sympathetic denervation was performed in all patients
without periprocedural complications. Patients were instructed
not to change their antihypertensive medications unless adverse
effects occurred. At 6 months after ablation, there was a slight, not
statistically signiﬁcant reduction in the number of antihyperten-
sive drugs from 5.6 (2.1) to 5.4 (2.0; Table 2). One patient stopped
taking a direct renin-inhibitor, one patient stopped taking a
calcium-channel blocker, one patient stopped taking a vasodilator,
and one patient stopped taking an aldosterone antagonist.
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Table 1 | Baseline clinical characteristics and demographics.
Baseline ofﬁce systolic BP (mmHg) 189 (23)
Baseline ofﬁce diastolic BP (mmHg) 92 (15)
Age (years) 68.9 (7.0)
Sex (female) 3 (27.3)
Body-mass index (kg/m2) 29.0 (3.4)
Diabetes mellitus 4 (36.4)
Coronary artery disease 4 (36.4)
Left ventricular ejection fraction (%) 59.1 (3.0)
Hypercholesterolaemia 4 (36.4)
eGFR (mL/min/1.73m2) 75.0 (18.4)
Serum creatinine (μmol/L) 1.0 (0.2)
Data are mean (SD) or number (%). BP, blood pressure; eGFR, estimated
glomerular ﬁltration rate.
Table 2 | Antihypertensive medications before and 6months after
renal denervation.
Before renal
denervation
6months
follow-up
Number of antihypertensive drugs 5.6 (2.1) 5.4 (2.0)
Patients on ﬁve or more medications 6 (54.5) 6 (54.5)
PATIENTS RECEIVING (DRUG CLASS)
ACE inhibitors/ARBs 11 (100) 11 (100)
Direct renin inhibitor 6 (54.5) 5 (45.5)
β-Blockers 8 (72.7) 8 (72.7)
Calcium-channel blockers 9 (81.8) 8 (72.7)
Diuretics 11 (100) 11 (100)
Aldosterone antagonist 2 (18.2) 2 (18.2)
Vasodilators 2 (18.2) 1 (9.1)
α-Blockers 4 (36.4) 3 (27.3)
Centrally acting sympatholytics 8 (72.7) 8 (72.7)
Data are mean (SD) or number (%). ACE, angiotensin-converting enzyme; ARB,
angiotensin-receptor blocker.
At baseline, overall mean sitting ofﬁce systolic BP was
189± 23 mmHg, and mean sitting ofﬁce diastolic BP was
92± 15 mm Hg, with a heart rate of 67± 11 bpm. Renal den-
ervation signiﬁcantly reduced systolic (−30.4± 27.7 mm Hg;
p= 0.007) but not diastolic (−2.9± 16.1 mm Hg; P= 0.648) BP
at 6 months after the procedure. Nine of the 11 patients (81.8%)
were responders to RDN as deﬁned by a reduction in systolic ofﬁce
BP of >10 mmHg.
Renal sympathetic denervation had signiﬁcant effects on
BP variability: It reduced SDsys by 20.1% from 16.9± 4.6
to 13.5± 2.5 mmHg (p= 0.003), MAXsys by 17.8 mmHg from
190± 22 to 172± 20 mmHg (p< 0.001), and Δmaxsys by 25%
from 40± 15 to 28± 7 (p= 0.006; Table 3; Figures 1A,C,E).
Reductions of SDsys, MAXsys, and Δmaxsys were observed in
10/11 (90.9%), 11/11 (100%), and 9/11 (81.8%), respectively.
Changes were also signiﬁcant when the coefﬁcient of varia-
tion of systolic BP was considered (p = 0.024). Correspond-
ing changes of BP variability in diastolic pressures were also
signiﬁcant (p= 0.007, p= 0.043, and p= 0.011 for SDdia, MAXdia,
and Δmaxdia, respectively; Table 3; Figures 1B,D,F).
We also noted signiﬁcant effects of RDN on 24-h SDsys and
SDdia when assessed for daytime but not for night-time (Table 3).
Renal denervation also reduced the morning surge assessed by
maximum increase of systolic and diastolic BP between 4 AM and
10 AM.
In contrast to effects of RDNon ofﬁce systolic BP,RDNdemon-
strated a less pronounced reduction in mean systolic BP assessed
by means of ABPM, which did not reach the level of statisti-
cal signiﬁcance (Figure 2). Six months after RDN, mean systolic
BP was reduced by 7 mmHg from 149± 19 to 142± 18 mmHg
(p= 0.086).
We did not ﬁnd any statistically signiﬁcant correlation between
RDN-related changes of BP variability (i.e., BP variability before
minus BP variability after RDN) and RDN-related changes of
mean BP levels, neither for systolic nor for diastolic BP. In par-
ticular, the correlation between RDN-related change of SDsys and
RDN-related changeof Meansys was found−0.06 (p = 0.856). This
remained true,when changes of BP variabilitywere correlatedwith
changes of ofﬁce BP, when day- and night-time were separately
analyzed or when analyses were restricted to RDN-responders.
DISCUSSION
The ﬁndings of our study indicate that RDN has signiﬁcant effects
on 24-h BP variability and instability in patients with therapy-
refractory arterial hypertension. Reduction of 24-h BP variability
by means of standard deviation of systolic BP was present in 10
out of 11 patients. RDN was also found to affect other estimates
of BP variability and instability such as the maximum systolic
BP or the maximum difference between consecutive BP readings.
Importantly, changes in BP variability and instability before and
after RDN were not correlated with changes in 24-h mean levels
of BP which were less pronounced.
Catheter-based RDN is a novel treatment option for patients
with treatment-resistant arterial hypertension. Its potential in
reducing ofﬁce BP has been demonstrated in one observational
(Krum et al., 2009) and one randomized trial (Esler et al., 2010).
In our study RDN reduced systolic ofﬁce BP by 30± 28 mmHg
which is practically identical to the results noted in previous stud-
ies (Krum et al., 2009; Esler et al., 2010). RDN’s effect on reducing
BP is most likely carried by a decline in renal and central sym-
pathetic activity (Krum et al., 2009; Esler et al., 2010). Published
studies investigating the effect of RDN on 24-h ABPM primarily
focus on reporting mean BP values, which according to our results
are less affected by RDN. In the Symplicity-II trial RDN reduced
mean 24-h systolic BP by only 11± 15 mmHg (Esler et al., 2010).
However, the analysis of 24-h BP proﬁles provides important
insights into (patho-) physiological regulations and prognostic
information beyond assessment of mean BP. Over 20 years ago,
Parati et al. (1987) demonstrated in 108 hypertensive patients
that the standard deviation of systolic BP was associated with end
organ damage independently from mean systolic BP. Several other
studies conﬁrmed the independent value of 24-h BP variability
in predicting organ damage (Mancia et al., 2001). Increased BP
variability also proved as a signiﬁcant and independent predic-
tor of clinical events, particularly of stroke, both in patients with
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Table 3 | BP variability, instability, and mean levels of BP at baseline and 6months after ablation.
Systolic BP Diastolic BP
Before renal
denervation
6months
follow-up
p-Value Before renal
denervation
6months
follow-up
p-Value
BPVARIABILITY AND INSTABILITY (ABPM)
Standard deviation, mmHg
24h 16.9±4.6 13.5±2.5 0.003 11.2±2.9 8.6±1.9 0.007
Daytime (10 AM–8 PM) 15.1±4.1 11.7±2.1 0.005 10.7±3.5 7.5±1.3 0.010
Night-time (12 AM–6 AM) 12.7±6.1 10.0±4.4 0.365 9.1±3.8 7.5±3.1 0.175
Coefﬁcient of variation 0.11±0.03 0.09±0.02 0.041 0.14±0.03 0.11±0.02 0.024
Maximum (24 h), mmHg 190±22 172±20 <0.001 112±25 98±18 0.043
Δmax of consecutive readings (24 h), mmHg 40±15 28±7 0.006 37±11 20±5 0.011
Maximum increase from 4 AM to 10 AM, mmHg 53±19 40±17 0.058 32±20 25±11 0.035
MEAN LEVELS (OFFICE ANDABPM)
Ofﬁce BP, mmHg 189±23 158±24 0.007 92±15 88±17 0.648
Mean ABPM, mmHg
24h 149±19 142±18 0.086 82±17 79±15 0.167
Daytime (10 AM–8 PM) 155±22 145±22 0.083 85±17 81±16 0.206
Night-time (12 AM–6 AM) 137±17 136±16 0.966 74±15 74±14 0.781
ABPM, ambulatory blood pressure monitoring; BP, blood pressure.
pre-existent hypertension (Pringle et al., 2003) and in the general
population (Mancia et al., 2007a). However, not all studies did
ﬁnd the predictive value of 24-h BP variability to be independent
from mean BP (Hansen et al., 2010). Other investigations assessed
BP variability over longer time scales by analyzing day-to-day or
visit-to-visit BP variability, which might capture different facets
of BP regulations. In most of these studies, day-to-day or visit-to-
visit variability was a strong and independent predictor of stroke
(Kikuya et al., 2000), cardiovascularmortality (Kikuya et al., 2000),
or all causemortality (Muntner et al., 2011;Hsieh et al., 2012). This
was true for studies including the general population (Kikuya et al.,
2000), patients with previous transitory ischemic attack (Rothwell
et al., 2010b), patients with treated hypertension (Rothwell et al.,
2010b), or type 2 diabetics (Hsieh et al., 2012). Additional markers
of BP instability such as the maximum observed systolic BP were
also predictive for clinical events (Rothwell et al., 2010b).
It might be suggested that drugs, which favorably affect mean
BP, also reduce BP variability. However, this might not be true
as recent ﬁndings in different populations suggest (Frattola et al.,
2000; Rothwell et al., 2010a; Webb et al., 2010; Webb and Roth-
well, 2011; Zhang et al., 2011). Only calcium antagonists have
been shown to reduce BP variability (visit-to-visit as well as 24-h),
while β-blockers, angiotensin-converting enzyme inhibitors, and
angiotensin II receptor antagonists seem to exhibit opposite effects
(Frattola et al., 2000; Rothwell et al., 2010a;Webb et al., 2010;Webb
and Rothwell, 2011; Zhang et al., 2011). These ﬁndings are alarm-
ing, as patients with residual BP variability on treatment have an
adverse prognosis despite control of mean BP (Rothwell et al.,
2010b).
Despite awareness of the prognostic role of BP variability in
the development of target organ damage and outcome a thor-
ough knowledge of its underlyingmechanisms is currently limited.
It is very likely that alterations in autonomic function including
increased sympathetic activity and depressed baroreﬂex sensitiv-
ity are involved in increased BP variability (Schillaci et al., 2011).
As baroreﬂex function ensures homeostasis, blunted baroreﬂex
function may result in exaggerated BP ﬂuctuations in response
to extrinsic or intrinsic stimuli (Mancia et al., 1997). Since RDN
has been shown to reduce renal and total sympathetic activity
(Schlaich et al., 2009) and thus might exhibit favorable effects on
baroreﬂex function in patients with sympathetic overactivity, it is
plausible to assume that RDN leads to beneﬁcial effects on BP vari-
ability. Additionally, other vascular mechanisms of BP variability
have been proposed including alterations of arterial distensibility
(Dabire et al., 2002).
A correct quantiﬁcation of BP variability is of crucial impor-
tance. In the present study we used the simplest and probably
most established measure of 24-h BP variability which is the stan-
dard deviation of BP. However, we are also aware of the fact
that this approach has some shortcomings, as it is inﬂuenced by
physiological variations such as day-night BP changes. Different
mathematical approaches have been proposed to overcome this
limitation (Mena et al., 2005;Mancia et al., 2007a). Separate assess-
ment of day and night periods might be the most effective one. We
also noted highly signiﬁcant effects of RDN on daytime but not
on night-time variations. A possible explanation for this lack of
signiﬁcance might be the reduced frequency of BP readings during
night. Another possible explanation, however, could be that day-
and night-time variations are differently affected by RDN with
sympathetic overactivity playing its predominant role in affect-
ing BP variability mainly during daytime. As recently suggested
(Stergiou and Parati, 2011),BP instability was assessed by themax-
imum systolic BP, which has been recently found to be a strong
and independent predictor of stroke (Rothwell et al., 2010b).
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FIGURE 1 | Effect of renal sympathetic denervation (RDN) on blood
pressure (BP) variability and instability: standard deviation of systolic (A)
and diastolic (B) BP, maximum systolic (C) and diastolic (D) BP and
maximum difference of systolic (E) and diastolic (F) BP observed
between two consecutive readings before renal sympathetic
denervation and 6months thereafter.
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FIGURE 2 | Effect of renal sympathetic denervation (RDN) on
mean levels of blood pressure (BP): office systolic (A) and
diastolic (B) BP as well as mean levels of systolic (C) and
diastolic (D) blood BP on 24-h ambulatory BP monitoring
(ABPM) before renal sympathetic denervation and 6months
thereafter.
Our study has important clinical implications. Increased BP
variability and instability,which has been shown to predict adverse
prognosis can be effectively treated by RDN. Previous studies
have only identiﬁed calcium antagonists being able to reduce
BP variability (Rothwell et al., 2010a; Webb et al., 2010; Webb
and Rothwell, 2011; Zhang et al., 2011). Second, increased BP
variability might help to identify responders to RDN. In the
Symplicity-II study as much as 16% of the patients had RDN-
related decreases of systolic ofﬁce BP of less than 10 mmHg.
Third, previous studies identiﬁed increased BP variability as a
strong predictor of stroke, particularly in patients with previous
transitory ischemic attack (Rothwell et al., 2010b). Future stud-
ies should test whether this patient group might beneﬁt from
prophylactic RDN.
The limitations of our study need to be recognized. The study
design was non-randomized and observational. However, our
patients were well-controlled and antihypertensive treatment was
not intensiﬁed throughout the follow-up. Most of our patients
were on calcium antagonists which might be a confounding factor.
However, as therapy with calcium antagonists did not signiﬁcantly
change throughout theobservational period,wedonot believe that
intake of calcium antagonists affects our results. The sample size
of our study was small but sufﬁciently large to detect effects on the
primary variable, i.e., standard deviation of 24-h systolic BP. How-
ever, lack of signiﬁcance in reduction of 24-h mean BP (p= 0.083
and p= 0.167 for reductions of mean systolic and diastolic BP,
respectively) might be due to a lack of statistical power. The small
sample size also prevented us from analyzing effects of RDN on
end organ damage. Furthermore, our study provides no mech-
anistic explanations of our ﬁndings as measures of sympathetic
activity such as noradrenalin spillover or muscular sympathetic
nerve activity have not been obtained.
In conclusion, RDN has signiﬁcant beneﬁcial effects on
BP variability and instability in patients with therapy-
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refractory hypertension which are unrelated to and exceed
effects on mean levels of BP. Potential beneﬁcial effects of
RDN on prognosis in hypertensive patients might be sub-
stantially mediated via a reduction of BP variability and
instability.
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